Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, 3-period, single dose study to evaluate the safety and tolerability and pharmacokinetics of DS-1040 coadministered with Enoxaparin in Healthy Subjects.

Next Previous
X
Search
Trial Profile

An Open-label, 3-period, single dose study to evaluate the safety and tolerability and pharmacokinetics of DS-1040 coadministered with Enoxaparin in Healthy Subjects.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 03 Mar 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs DS 1040 (Primary) ; Enoxaparin sodium (Primary)
  • Indications Pulmonary embolism; Stroke
  • Focus Adverse reactions; Pharmacokinetics

    • Most Recent Events

    • 27 Feb 2020 Results evaluating the safety and tolerability of DS-1040 along with the effect on DS-1040 pharmacokinetic (PK) parameters, when dosed alone or when coadministered with aspirin (NCT02071004), clopidogrel (NCT02560688), or enoxaparin in healthy subjects published in the Journal of Clinical Pharmacology
    • 07 Apr 2017 New trial record
    • 18 Mar 2017 Results presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top